Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Article 2021 en
Authors
EK
Efstathios Kastritis
GP
Giovanni Palladini
MM
Monique C. Minnema
Abstract
1 min read
Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, NCT03201965.).
Discussion(0)
No comments yet. Be the first to comment.